Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas A Di Prospero

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Nature Reviews. Genetics|October 6, 2005
Therapeutics development for triplet repeat expansion diseasesNicholas A Di Prospero, Kenneth H Fischbeck
Journal of Neurology|March 14, 2009
Clinical experience with high-dose idebenone in Friedreich ataxiaJörg B Schulz, Nicholas A Di Prospero, Kenneth Fischbeck
Pediatric Diabetes|December 23, 2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetesWilliam V Tamborlane, David Polidori, Domenick Argenti, et al.
The Lancet. Neurology|September 11, 2007
Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trialNicholas A Di Prospero, Angela Baker, Neal Jeffries, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
Predictors of progression in patients with Friedreich ataxiaAlison La Pean, Neal Jeffries, Chelsea Grow, et al.
Neurobiology of Disease|April 18, 2008
Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamicsBarrington G Burnett, Jaime Andrews, Srikanth Ranganathan, et al.
Clinical Obesity|January 21, 2021
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging studyNicholas A Di Prospero, Jaqueline Yee, Mary E Frustaci, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participantsDamayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, et al.
Nature Reviews. Neuroscience|April 19, 2012
Impaired mitochondrial function in psychiatric disordersHusseini Manji, Tadafumi Kato, Nicholas A Di Prospero, et al.
Journal of Cardiac Failure|October 8, 2017
The Subclinical Cardiomyopathy of Friedreich's Ataxia in a Pediatric PopulationJonathan F Plehn, Keren Hasbani, Inez Ernst, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Nature Reviews. Genetics|October 6, 2005
Therapeutics development for triplet repeat expansion diseasesNicholas A Di Prospero, Kenneth H Fischbeck
Journal of Neurology|March 14, 2009
Clinical experience with high-dose idebenone in Friedreich ataxiaJörg B Schulz, Nicholas A Di Prospero, Kenneth Fischbeck
Pediatric Diabetes|December 23, 2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetesWilliam V Tamborlane, David Polidori, Domenick Argenti, et al.
The Lancet. Neurology|September 11, 2007
Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trialNicholas A Di Prospero, Angela Baker, Neal Jeffries, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
Predictors of progression in patients with Friedreich ataxiaAlison La Pean, Neal Jeffries, Chelsea Grow, et al.
Neurobiology of Disease|April 18, 2008
Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamicsBarrington G Burnett, Jaime Andrews, Srikanth Ranganathan, et al.
Clinical Obesity|January 21, 2021
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging studyNicholas A Di Prospero, Jaqueline Yee, Mary E Frustaci, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participantsDamayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, et al.
Nature Reviews. Neuroscience|April 19, 2012
Impaired mitochondrial function in psychiatric disordersHusseini Manji, Tadafumi Kato, Nicholas A Di Prospero, et al.
Journal of Cardiac Failure|October 8, 2017
The Subclinical Cardiomyopathy of Friedreich's Ataxia in a Pediatric PopulationJonathan F Plehn, Keren Hasbani, Inez Ernst, et al.
Pageof 3